Sanchine三精品牌怎么样 申请店铺

我要投票 Sanchine三精在补钙行业中的票数:70 更新时间:2024-12-22
Sanchine三精是哪个国家的品牌?「Sanchine三精」是 哈药集团三精制药有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人芦传有在2015期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
Sanchine三精怎么样

三精制药始建于1950年,初期以生产肌肉和静脉水针剂为主,是黑龙江省最早的专业化生产水针剂和国内最早引进国外水针剂一连机生产设备的企业,是最早通过国家GMP认证的医药企业之一。公司现总占地面积110万平方米,员工总数近6000人,是以OTC产品、处方药与保健食品为主、医药原料和制剂并重的综合性制药企业。2004年,“三精”品牌被国家工商总局认定为“驰名保护”。2011年5月13日,“三精”品牌在“2011中国最有价值品牌评价”中,经权威机构认定,品牌价值为68.93亿元人民币。

目前,三精制药拥有下属子公司15家,其中工业子公司8家、商业子公司5家、其他相关产业子公司2家。截至目前,公司口服液、口服溶液剂、小容量注射剂(非最终灭菌)、冻干粉针剂、片剂、粉针剂、胶囊剂、颗粒剂、合剂、糖浆剂、洗剂、茶剂、散剂13个剂型及无菌原料药(磷霉素钠、炎琥宁)、原料药(拉西地平、盐酸罗沙替丁醋酸酯)均通过2010版GMP认证。其中,口服液剂型产品年生产能力达16亿支。公司主导产品包括葡萄糖酸钙口服溶液、葡萄糖酸锌口服液、双黄连口服液、司乐平片等。近年来,通过药品、保健品的新产品立项研发,不断完善产品线,丰富产品阵容。

六十余年的制药经验,先进的技术设备,一流的管理手段,完善的科研开发体系,使“三精”牌在国内外丰享盛誉。三精一直将产品和服务视为核心竞争力,同时高度重视产品的研发,2004年建成较具规模的研发中心,已成为黑龙江省药物制剂工程技术研究中心、黑龙江省西药制剂重点实验室,承担“十一五”“重大新药创制”科技重大专项——“新型口服缓控释制剂及工艺技术平台”课题和“十二五”“重大新药创制”科技重大专项——“抗阿尔茨海默病药重酒石酸卡巴拉汀及其胶囊的研究开发”课题。2008年,公司成为“国家首批创新型企业”,2012年入选国家火炬计划重点高新技术企业。公司还先后荣获了全国质量管理先进企业、全国守合同重信用企业、全国医药系统优秀企业、全国“五·一劳动奖状”先进集体、“全国企业文化优秀成果奖”、“全国医药行业药品质量诚信建设示范企业”、“21315国际质量信用AAA++级”、“中国优秀诚信企业”、“中国化学制药行业工业企业综合实力百强”企业、黑龙江省“科技创新优秀企业奖”等荣誉称号。

Sanjing pharmaceutical was founded in 1950. At the early stage, it mainly produces muscle and intravenous water injection. It is the first professional enterprise in Heilongjiang Province to produce water injection and the first enterprise in China to introduce foreign water injection production equipment. It is also one of the first pharmaceutical enterprises to pass the national GMP certification. The company now covers an area of 1.1 million square meters and employs nearly 6000 people. It is a comprehensive pharmaceutical enterprise focusing on OTC products, prescription drugs and health food, with equal emphasis on pharmaceutical raw materials and preparations. In 2004, "three fine" brand was recognized as "well-known protection" by the State Administration for Industry and commerce. On May 13, 2011, in the "2011 China's most valuable brand evaluation", the brand value of "three fine" was recognized by the authority as RMB 6.893 billion. At present, Sanjing pharmaceutical has 15 subsidiaries, including 8 Industrial subsidiaries, 5 Commercial subsidiaries and 2 other related industrial subsidiaries. Up to now, 13 dosage forms of the company's oral liquid, oral solution, small volume injection (non final sterilization), freeze-dried powder injection, tablet, powder injection, capsule, granule, mixture, syrup, lotion, tea, powder, sterile API (fosfomycin sodium, Yanhuning), API (lacidipine, rosattidine hydrochloride acetate) have passed GMP certification of 2010 version. Among them, the annual production capacity of oral liquid dosage products reached 1.6 billion. The company's leading products include calcium gluconate oral solution, zinc gluconate oral solution, Shuanghuanglian oral solution, and silepin tablets. In recent years, through the research and development of new products of drugs and health products, the product line has been continuously improved and the product lineup has been enriched. With more than 60 years of pharmaceutical experience, advanced technology and equipment, first-class management means, and perfect scientific research and development system, the "three refined" brand enjoys a good reputation at home and abroad. Sanjing has always regarded products and services as its core competitiveness, and attached great importance to product research and development. In 2004, it established a relatively large-scale research and development center, which has become Heilongjiang pharmaceutical engineering and technology research center and Heilongjiang western pharmaceutical Key Laboratory, undertaking the major science and technology project of "11th Five Year plan" and "major new drug creation" -- new oral sustained and controlled release preparations and technology "Platform" project and "12th Five Year Plan" science and technology major project of "major new drug creation" - research and development of anti Alzheimer's disease drug kabalatin tartrate and its capsule ". In 2008, the company became "the first batch of national innovative enterprises", and in 2012, it was selected as a key high-tech enterprise in the national torch plan. The company has also won the national advanced quality management enterprise, the national contract abiding and trustworthy enterprise, the national excellent pharmaceutical system enterprise, the national advanced collective of "May 1st Labor Award", "national enterprise culture excellent achievement award", "national pharmaceutical industry pharmaceutical quality and integrity construction demonstration enterprise", "21315 International quality and credit AAA + + level", "China excellent and integrity enterprise" "Top 100 enterprises with comprehensive strength in China's chemical and pharmaceutical industry" and "science and technology innovation excellent enterprise award" of Heilongjiang Province, etc.

本文链接: https://brand.waitui.com/41c6b1011.html 联系电话:0451-86627550

千城特选小程序码

7×24h 快讯

新易盛:涉嫌违反限制性规定转让股票等行为 公司实际控制人高光荣被立案调查

新易盛公告,公司控股股东、实际控制人、董事长高光荣于2024年12月20日收到中国证券监督管理委员会签发的《立案通知书》,因“涉嫌违反限制性规定转让股票”等行为被立案调查。该事项现处于调查阶段,具体情况尚待有关部门的最终确认。高光荣因其个人转让股票事宜被立案调查,与公司经营无关,不会对公司产生影响,公司生产经营情况一切正常。公司将持续关注上述事项的进展情况,并严格按照有关法律、法规的规定和要求,及时履行信息披露义务。

23分钟前

高德地图首发全域车道级导航

12月21日,蔚来NIO DAY上,高德地图全域车道级导航同蔚来智能电动行政旗舰ET9合作亮相,这也是高德地图车机版首发全域车道级服务,即将在蔚来更多车型得到升级搭载。

23分钟前

香港财政司司长陈茂波:香港未来须推动更多跨境合作创新,进一步提升金融市场体量

香港财政司司长陈茂波12月22日在司长随笔中表示,香港未来必须推动更多制度创新、产品创新与跨境合作创新,例如开拓内地通过香港与更多新兴市场的联系,同时巩固好与传统市场的协作,进一步提升香港金融市场的体量、流动性,更好满足科技变革与地缘政局下企业与其他机构的筹融资需要,让香港国际金融中心内涵更丰富、优势更巩固、国际影响力更显著。(界面)

23分钟前

湖畔实验室发布2024年创新成果

36氪获悉,12月22日,湖畔实验室(数据科学与应用浙江省实验室)发布包括AI多癌早筛、气象大模型等在内的多项年度创新成果。实验室用前沿AI技术迎战医疗、能源、农业、集成电路等产业难题,部分成果达到国际领先水平,并实现快速的落地应用,构建起“科技+产业”的正循环。作为浙江由民企牵头建设的省实验室,湖畔实验室成立于2020年7月,依托阿里巴巴达摩院建设,聚焦数据科学与应用领域。大会上,湖畔实验室进行了年度教科人一体化优秀项目颁奖和国家级博士后工作站揭牌,并与杭州电子科技大学战略合作签约。

23分钟前

卡塔尔警告欧盟,欧盟新指令或致卡方停止向欧盟输送天然气

12月22日,卡塔尔能源事务国务大臣、卡塔尔能源公司总裁兼首席执行官萨阿德·卡比警告,欧盟新指令或导致卡塔尔停止向欧盟输送天然气。卡比说,如果欧盟实施《企业可持续发展尽职调查指令》,让卡塔尔能源公司损失5%的收入,那卡方宁愿不进入欧洲市场。他强调,他不是在虚张声势,因为卡塔尔能源公司的收入属于卡塔尔政府和人民,没有人会接受损失这么多资金。卡比称,欧盟应该对《企业可持续发展尽职调查指令》进行审查。欧盟理事会今年5月批准通过《企业可持续发展尽职调查指令》。该指令将在未来几年分阶段实施,对在欧盟运营的具有一定规模的企业引入强制性的环境尽职调查要求,旨在减轻或终止对环境造成的不利影响。对于违反该指令的企业,最高可被处以全球营业额5%的罚款。

23分钟前

本页详细列出关于瑞年RealNutri的品牌信息,含品牌所属公司介绍,瑞年RealNutri所处行业的品牌地位及优势。
咨询